LEADER 01430nam  2200469   450 
001 9910155232703321
005 20150814081115.0
010   $a1-62257-153-3
035   $a(CKB)3710000000973779
035   $a(MiAaPQ)EBC4787183
035   $a(EXLCZ)993710000000973779
100   $a20170130h20122012  uy             0
101 0 $aeng
135   $aurcnu||||||||
181   $2rdacontent
182   $2rdamedia
183   $2rdacarrier
200 00$aFDA drug approval $eelements and considerations /$fTimothy I. King and Thomas R. Baker, editors
210  1$aNew York, [New York] :$cNova Biomedical,$d2012.
210  4$dİ2012
215   $a1 online resource (154 pages) $ccolor illustrations
225 1 $aPharmacology - Research, Safety Testing and Regulation
300   $aIncludes index.
311   $a1-62257-091-X 
410  0$aPharmacology-research, safety testing, and regulation series.
606   $aDrug approval$zUnited States
606   $aClinical trials$zUnited States
607   $aUnited States$2fast
615  0$aDrug approval
615  0$aClinical trials
676   $a615.1072/4
702   $aKing$b Timothy I.
702   $aBaker$b Thomas R.
712 02$aKing, Timothy I.,
712 02$aBaker, Thomas R.,
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910155232703321
996   $aFDA drug approval$92882540
997   $aUNINA